CR20110360A - Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica

Info

Publication number
CR20110360A
CR20110360A CR20110360A CR20110360A CR20110360A CR 20110360 A CR20110360 A CR 20110360A CR 20110360 A CR20110360 A CR 20110360A CR 20110360 A CR20110360 A CR 20110360A CR 20110360 A CR20110360 A CR 20110360A
Authority
CR
Costa Rica
Prior art keywords
piridin
pirazol
ona
therapeutics
derivatives
Prior art date
Application number
CR20110360A
Other languages
English (en)
Inventor
Altenburger Jean-Michel
Fossey Valerie
Illiano Stephane
Manette Geraldine
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807475A external-priority patent/FR2940652B1/fr
Priority claimed from FR0904091A external-priority patent/FR2949468B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20110360A publication Critical patent/CR20110360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La invención se refiere a los compuestos que responden a la fórmula (i), en estado de base o de sal por adición de un ácido. (I) en la cual n es igual a o, 1, 2, 3 o 4; m es igual a O , 1 o 2; o es igual a 0 o 1; X representa un grupo -CH2, -CH(R')- o un heteroátomo seleccionado entre O y S, entendiéndose que R' representa un grupo alquilo(C1-C5)alquilo, alcoxi(C1-C5), -CH2-arilo, -C(O)R5 o-COOR5.
CR20110360A 2008-12-29 2011-06-23 Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica CR20110360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0807475A FR2940652B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
FR0904091A FR2949468B1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CR20110360A true CR20110360A (es) 2011-10-13

Family

ID=41728182

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110360A CR20110360A (es) 2008-12-29 2011-06-23 Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica

Country Status (34)

Country Link
US (2) US8697731B2 (es)
EP (1) EP2382215B1 (es)
JP (1) JP5865704B2 (es)
KR (1) KR101630475B1 (es)
CN (1) CN102333776B (es)
AR (1) AR074916A1 (es)
AU (1) AU2009334570B2 (es)
BR (1) BRPI0923875A2 (es)
CA (1) CA2748413A1 (es)
CO (1) CO6400145A2 (es)
CR (1) CR20110360A (es)
CY (1) CY1115635T1 (es)
DK (1) DK2382215T3 (es)
EA (1) EA019774B1 (es)
EC (1) ECSP11011164A (es)
ES (1) ES2511917T3 (es)
HK (1) HK1163679A1 (es)
IL (1) IL213790A (es)
MA (1) MA32978B1 (es)
MX (1) MX2011007061A (es)
MY (1) MY155244A (es)
NI (1) NI201100132A (es)
NZ (1) NZ593797A (es)
PA (1) PA8856101A1 (es)
PE (1) PE20120338A1 (es)
PL (1) PL2382215T3 (es)
PT (1) PT2382215E (es)
SG (1) SG172422A1 (es)
SI (1) SI2382215T1 (es)
SM (1) SMT201400157B (es)
TN (1) TN2011000308A1 (es)
TW (1) TWI441828B (es)
WO (1) WO2010076525A1 (es)
ZA (1) ZA201104785B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY155244A (en) 2008-12-29 2015-09-30 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
JP6126078B2 (ja) * 2012-03-30 2017-05-10 第一三共株式会社 ４−アルカノイルアミノ−３−ピラゾロン誘導体
CN102731384B (zh) * 2012-07-10 2016-04-06 南开大学 一种6-甲基烟酸叔丁酯的合成方法
ES2660914T3 (es) * 2013-03-29 2018-03-26 Takeda Pharmaceutical Company Limited Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
CN105061316B (zh) * 2015-07-17 2017-12-22 苏州大学 稠环类化合物、制备方法和用途
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3917469A1 (de) * 1989-05-30 1990-12-06 Bayer Ag Heterocyclylpyridine
DE4023488A1 (de) 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
PE20071020A1 (es) * 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
WO2008047198A1 (en) * 2006-10-16 2008-04-24 Pfizer Products Inc. Therapeutic pyrazolyl thienopyridines
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
RU2009146851A (ru) * 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EP2382205B1 (fr) 2008-12-29 2014-04-23 Sanofi Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique comme activateurs de hif
MY155244A (en) 2008-12-29 2015-09-30 Sanofi Sa Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof

Also Published As

Publication number Publication date
CO6400145A2 (es) 2012-03-15
WO2010076525A1 (fr) 2010-07-08
IL213790A (en) 2015-09-24
DK2382215T3 (da) 2014-10-27
SI2382215T1 (sl) 2020-06-30
US20140194470A1 (en) 2014-07-10
AU2009334570A1 (en) 2011-07-21
HK1163679A1 (en) 2012-09-14
JP2012513977A (ja) 2012-06-21
AU2009334570B2 (en) 2016-06-09
ES2511917T3 (es) 2014-10-23
ZA201104785B (en) 2012-09-26
SMT201400157B (it) 2015-01-15
EP2382215A1 (fr) 2011-11-02
KR20110111437A (ko) 2011-10-11
BRPI0923875A2 (pt) 2015-07-21
NZ593797A (en) 2013-01-25
TN2011000308A1 (fr) 2012-12-17
PT2382215E (pt) 2014-10-16
EA201170900A1 (ru) 2012-02-28
NI201100132A (es) 2011-11-01
MY155244A (en) 2015-09-30
CA2748413A1 (fr) 2010-07-08
JP5865704B2 (ja) 2016-02-17
US20110301148A1 (en) 2011-12-08
MA32978B1 (fr) 2012-01-02
PL2382215T3 (pl) 2015-01-30
ECSP11011164A (es) 2011-07-29
MX2011007061A (es) 2011-12-16
EP2382215B1 (fr) 2014-07-16
EA019774B1 (ru) 2014-06-30
US9359329B2 (en) 2016-06-07
IL213790A0 (en) 2011-07-31
TWI441828B (zh) 2014-06-21
AR074916A1 (es) 2011-02-23
US20160137627A9 (en) 2016-05-19
KR101630475B1 (ko) 2016-06-14
US8697731B2 (en) 2014-04-15
PE20120338A1 (es) 2012-04-30
CN102333776B (zh) 2014-05-21
CN102333776A (zh) 2012-01-25
PA8856101A1 (es) 2010-07-27
SG172422A1 (en) 2011-07-28
CY1115635T1 (el) 2017-01-04
TW201028424A (en) 2010-08-01

Similar Documents

Publication Publication Date Title
CR20110360A (es) Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica
CR11596A (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica
CR11547A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
CR20120261A (es) Derivados de piridino-piridinonas, su preparación y su aplicación en terapéutica
ES2571483T3 (es) Producto intermedio para producir un éster de ácido sulfónico cíclico
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
MA32721B1 (fr) Composition pharmaceutique solide
EA201201268A1 (ru) Синтез производных альфа-токоферолхинона и способы их применения
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
BR112012029954A2 (pt) composto de poliamida
ECSP099339A (es) Derivados de pirrol, su preparación y su utilización en terapéutica
MA32165B1 (fr) Composition pharmaceutique
BR112015009988A2 (pt) melhoramentos em compostos orgânicos ou relativos
CR8677A (es) Derivados de piridoindolona sustituidos en -6, su preparacion, su aplicacion en terapeutica
AR093270A1 (es) METODO DE PREPARACION DE COMPUESTOS DE a-GALACTOSILCERAMIDAS
CR11432A (es) Acidos carboxilicos bifenil y derivados de los mismos
AR074629A1 (es) Derivados de 1-bencil-cinolin-4-(1h)-ona sustituidos, su preparacion, composiciones farmaceuticas y su uso en el tratamiento de patologias asociadas con receptores de los cannabinoides cb2
CU20120041A7 (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112014020610B8 (pt) composto, métodos para produzir e para purificar a forma (z) de um composto, e para produzir a forma (z) de um derivado de tetrazoliloxima
CR20110306A (es) Derivados de morfina-6-glucuronido, su preparación y su aplicación en terapéutica